Financial reports
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
NT 10-Q
Notice of late quarterly filing
16 Aug 22
10-Q
2022 Q2
Quarterly report
16 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
31 Mar 22
10-Q
2021 Q3
Quarterly report
9 Nov 21
10-Q
2021 Q2
Quarterly report
5 Aug 21
10-Q
2021 Q1
Quarterly report
6 May 21
10-K
2020 FY
Annual report
16 Mar 21
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
25 Jan 23
8-K
Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution
9 Jan 23
8-K
Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update
14 Nov 22
8-K
Termination of a Material Definitive Agreement
29 Sep 22
8-K
Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
15 Aug 22
8-K
Amendments to Articles of Incorporation or Bylaws
14 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
3 Jun 22
8-K
Entry into a Material Definitive Agreement
23 May 22
8-K
Calithera Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
10 May 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Apr 22
Registration and prospectus
15-12G
Securities registration termination
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Mar 23
Proxies
DEFM14A
Proxy related to merger
5 Jun 23
PREM14A
Preliminary proxy related to merger
26 May 23
DEFA14A
Additional proxy soliciting materials
19 May 23
DEFA14A
Additional proxy soliciting materials
25 Jan 23
DEFA14A
Additional proxy soliciting materials
9 Jan 23
DEFA14A
Additional proxy soliciting materials
23 May 22
DEFA14A
Additional proxy soliciting materials
20 Apr 22
DEF 14A
Definitive proxy
20 Apr 22
PRE 14A
Preliminary proxy
8 Apr 22
DEFA14A
Additional proxy soliciting materials
23 Apr 21
Other
CT ORDER
Confidential treatment order
15 Jun 23
EFFECT
Notice of effectiveness
20 Mar 23
EFFECT
Notice of effectiveness
20 Aug 20
CORRESP
Correspondence with SEC
17 Aug 20
UPLOAD
Letter from SEC
14 Aug 20
CT ORDER
Confidential treatment order
10 May 18
CT ORDER
Confidential treatment order
1 May 18
EFFECT
Notice of effectiveness
18 Aug 17
CORRESP
Correspondence with SEC
16 Aug 17
UPLOAD
Letter from SEC
15 Aug 17
Ownership
SC 13D/A
TAKEDA PHARMACEUTICAL CO LTD
26 May 23
4
Change in insider ownership
26 May 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 23
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 23
SC 13G/A
PRIMECAP MANAGEMENT CO/CA/
9 Feb 23
SC 13G/A
PRIMECAP MANAGEMENT CO/CA/
9 Feb 23
SC 13G/A
INCYTE CORP
8 Feb 23
4
DEEPIKA PAKIANATHAN
31 Jan 23
4
Eric Sjogren
25 Jan 23
4
Emil Kuriakose
25 Jan 23